Examine This Report on CFSE
Oral HDAC inhibitor tucidinostat in clients with relapsed or refractory peripheral T-cell lymphoma: phase IIb outcomesThe aim of the present period IIb review was to evaluate the efficacy and safety of tucidinostat in individuals with R/R ATLL. This is actually the first study for individuals with R/R aggressive ATLL by using a cure record of mogam